Small molecule · Inhibitor of Plasma kallikrein (KLKB1) · developed by Biocryst
Berotralstat is an oral plasma kallikrein inhibitor that binds plasma kallikrein and blocks its proteolytic activity, reducing excess bradykinin generation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05453968 | Phase 3 | Hereditary Angioedema | Active not recruiting | BCRX |
| NCT03873116 | Phase 3 | Hereditary Angioedema, HAE | Completed | BCRX |
| NCT03472040 | Phase 2/3 | Hereditary Angioedema | Completed | BCRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
PediatricHAEHereditary AngioedemaHereditary Angioedema, HAEProphylaxis
Updated Oct 11, 2026. Something wrong or missing? Report it on the BCRX page.
See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BCRX catalysts and pipeline →